Asthma Clinical Trial
Official title:
The Effect of Body Awareness Therapy on Postural Stability, Balance and Fear of Falling in Patients With COPD
Chronic obstructive pulmonary disease (COPD) is one of the serious diseases with a high
prevalence and mortality, which adversely affects the quality of life, and is expected to
rank third in the global burden of disease in 2020. Although the primary pathophysiology of
the disease is pulmonary, it is emphasized that extrapulmonary involvement and comorbid
conditions adversely affect the severity and prognosis of the disease. In the treatment
guidelines for COPD, extrapulmonary systems and symptoms should also be evaluated. In this
context, the number of studies on the effects of postural stability, balance and fall has
increased recently, especially in COPD patients. Although the efficacy of pulmonary
rehabilitation (PR) in COPD is well defined, it provides minimal gains in postural control
and balance. Alternative therapies are needed to improve postural stability, balance and fall
in COPD patients.
Body Awareness Therapy (BAQ) is an alternative method developed by French exercise instructor
and psychotherapist Jacques Dropsy in the early 1970s following the emergence of the concept
of body awareness, adapted to rehabilitation programs by Swedish and Norwegian
physiotherapists. Traditional physiotherapy methods are the basis of BAQ. In the treatment,
sensory stimulation and movement quality, rhythm, coordination, breathing, relaxation,
balance, coordination and proprioceptive exercises give more space. In the literature, BAQ
decreases pain, fatigue, eating and sleep problems in chronic musculoskeletal or rheumatic
pain, coronary artery disease and neurological patient groups. It is seen to increase the
quality of exercise, coordination, balance, postural control, quality of life and the
integration between mind-body. Movement awareness and mind-body-behavior interaction
developed in BAQ can help regulate emotional, mental, social and behavioral factors that
affect health. In addition to improving coping skills and cognitive behaviors among COPD
patients, it can contribute to positive gains in better movement, respiratory control and
balance. The aim of this study is to investigate the effect of BAQ, which is integrated into
8-week pulmonary rehabilitation sessions, on postural stability, balance and fall conditions.
| Status | Recruiting |
| Enrollment | 32 |
| Est. completion date | February 2022 |
| Est. primary completion date | February 2021 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 40 Years to 80 Years |
| Eligibility |
Inclusion Criteria: - Diagnosis of COPD according to GOLD and willingness to participate - Age between 40-80 years - Clinically stable period - No serious hearing and vision problems Exclusion Criteria: - Patients with recurrent exacerbations reported (history of exacerbation in the last two months) - Having cognitive impairment (less than 24 Mini Mental Test scores) - Having diagnosed vision, hearing, vestibular or neurological problems that may affect balance - Having diagnosed orthopedic problems affecting mobility or having a history of surgical intervention - COPD patients receiving home oxygen therapy or frequent need of oxygen therapy - Patients with exercise-induced dyspnea - Patients with primary pulmonary hypertension or patients with pulmonary embolism - Congestive heart failure and severe coronary patients with coronary artery disease or by-pass surgery due to coronary artery disease - Patients with morbid obesity - Presence of systemic disease involving the lung and lung that would previously cause dyspnea other than COPD - Having received pulmonary rehabilitation in the last 12 months - Presence of unstable cardiovascular disease - SpO2<90% - Problems with understanding and co-operation in understanding tests |
| Country | Name | City | State |
|---|---|---|---|
| Turkey | Marmara University | Istanbul |
| Lead Sponsor | Collaborator |
|---|---|
| Marmara University |
Turkey,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Postural Stability | In our study, the postural stability levels of the cases will be evaluated with their feet wide open on the balance platform without any support. The subjects were asked to hold the ball at the midpoint of the circle on the screen opposite to the position and center of gravity of the individual and to keep it at the midpoint for 1 minute; During the measurement, right - left and anterior - posterior oscillations and overall performance levels of the subjects will be recorded. | 8 weeks | |
| Primary | Balance | Balance Master device will be used. Using a fixed 18 "x 60" force platform, the Balance Master determines the vertical force exerted by the patient's feet to measure the center of balance. | 8 weeks | |
| Primary | Fear of Falling | It will be evaluated by the Drop Efficacy Scale. ISI is a 10-item scale. They are asked to score between 1 and 10 to the questions. 1 means a lot of trust, 10 means no. A total score of 0 to 100 is obtained. If the total score is more than 70 points, there is fear of falling. | 8 weeks | |
| Secondary | Tiffeneau index for Pulmonary Function Test | Tiffeneau index, also called FEV1 / FVC ratio will be used. FEV1 / FVC ratio is defined as obstruction if less than 70% and restriction if more than 80%. | 8 weeks | |
| Secondary | The Medical Research Council Dyspnea Scale (mMRC) for dyspnea | The Medical Research Council Dyspnea Scale (mMRC) use to determine the degree of dyspnea on daily activities. The mMRC dyspnea scale determines the risk of future mortality and includes five dyspnea questions. The scale is scored between 0-4 degrees. Increased grade means severe dyspnea. | 8 weeks | |
| Secondary | 6-Minute Walk Test (6MWT) for functional capacity | The distance traveled by the subjects as fast as possible at their own walking speed for 6 minutes in a 30-meter straight corridor, but without running will be recorded in meters. The elongation of the distance indicates an increase in the functional capacity of the patient. | 8 weeks | |
| Secondary | Chronic Obstructive Pulmonary Disease Assessment Test (CAT) | Chronic Obstructive Pulmonary Disease Assessment Test (CAT): An eight-item, short, easy-to-use clinical test that evaluates the effects of COPD (cough, sputum, fatigue, confidence in leaving home) and deterioration in the patient's health. Scores range from 0-40. The higher the score, the higher the severity of the disease. | 8 weeks | |
| Secondary | Self-Efficacy Scale for the assessment of disease compliance: | Assessment of Disease Compliance will be evaluated by the Self-Efficacy Scale in Chronic Diseases. It was developed by Lorig et al. (1996) to measure self-efficacy perceptions of individuals with chronic disease. The scale consists of three main concepts and a total of 10 sub-dimensions. The scale is answered in likert type which determines the self-efficacy perception increasing from 1 to 10. Number 1 in the scale represents yok I have no confidence, and number 10 represents "I have full confidence". The total score of the individual is divided by the number of items and an average self-efficacy score is found. If this score is below 7, it means that strategies and problem-solving must be reassessed to prevent failure. A score of 7 or higher means that the individual has high self-efficacy and can achieve his / her thoughts. a minimum of 10 and a maximum of 100 points can be obtained from the survey. | 8 weeks |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
| Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
| Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
| Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
| Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
| Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
| Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
| Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
| Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
| Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
| Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
| Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
| Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
| Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
| Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
| Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
| Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
| Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
| Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|